HR+/HER2— breast cancer

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort

Wang S, Zhang Q, Jiang Z, Tong Z, Li W, Wang J, Ouyang Q, Yao T, Wang Y, Sun M, Wang X, Wang S, Zang[...]

By afschroeder • September 12, 2026